Planned Radiation in Axillary Management of Breast Cancer

Video

This video examines how planned radiation will impact management of the axilla in breast cancer patients undergoing mastectomy.

In this video, Henry Kuerer, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, discusses how planned radiation will impact management of the axilla in breast cancer patients undergoing mastectomy.

Kuerer spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago, and here highlights ongoing trials in this setting as well as a new ASCO Education Book on this topic, “Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery.”

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
Giving cilta-cel in earlier lines of therapy leverages stronger baseline immune health and a more favorable TME to deliver enhanced clinical outcomes.

Survival Benefit Seen With Cilta-Cel in Earlier Lines of Myeloma Treatment

Sabrina Serani
December 6th 2025
Article

Giving cilta-cel in earlier lines of therapy leverages stronger baseline immune health and a more favorable TME to deliver enhanced clinical outcomes.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

ORR Improvement Noted With Lisaftoclax Monotherapy in R/R Leukemia Subtypes

ORR Improvement Noted With Lisaftoclax Monotherapy in R/R Leukemia Subtypes

Tony Berberabe, MPH
December 6th 2025
Article

Results from a phase 2 trial showed an ORR of 62.5% in patients receiving lisaftoclax monotherapy for CLL/SLL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Tim Cortese
December 6th 2025
Article

Elevated LDH levels were associated with worse PFS and OS outcomes in patients with relapsed/refractory multiple myeloma treated with elranatamab.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Survival Similar With MMUD Grafts in GVHD Care Regardless of Match Level

Roman Fabbricatore
December 6th 2025
Article

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.